Background
The chronic inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD), are complex diseases caused by an interplay between genetic and environmental factors [
1].
The recent years have brought much progress regarding the genetics in IBD and the number of confirmed IBD associated loci and genes have risen dramatically [
2‐
7]. Yet, still, only part of the genetic contribution to disease risk may be explained by the identified genes [
8,
9]. Northern European populations, including the Danish, generally have low frequencies of the CD risk-associated variants of
CARD15 [
3,
10], and it is therefore of interest to search for more genetic determinants in these populations. Less progress has been achieved in the identification of environmental risk factors and gene-environmental interactions. Differences in environmental exposures and genetic heterogeneity between ethnic groups may have complicated the search for genetic and gene-environmental determinants.
The emerging picture of IBD pathogenesis is focused on the sequential occurrence of pivotal events leading to the initiation and subsequent perpetuation of inflammation [
11,
12]. First, the initial interaction between luminal constituents and intestinal epithelial cells leads to activation of the innate immune system [
11]. The recognition of highly conserved pathogen structures such as lipopolysaccharide (LPS), the main constituent of Gram-negative bacteria, by Toll-like receptors and other pattern recognition receptors on the epithelial and other immunologically active cells in the intestine, initiates the release of various cytokines and enzymes, including interleukins (IL) and heme oxygenase-1 [
13,
14]. Second, the inflammation will eventually become chronic due to defective regulation of the immune response. Therefore, polymorphisms in genes encoding cytokines and other molecules involved in the innate immune system, may affect the course of the inflammatory cascade and thereby the risk of developing IBD.
Activation of the pro-inflammatory IL-1β leads to production of prostaglandin E
2 (PGE
2) and nitric oxide (NO) via the induction of cyclo-oxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) among others [
15].
IL-1β knock-out mice have no spontaneous abnormalities, however, on challenge with LPS, a less pronounced acute phase response is observed, suggesting that IL-1β is required for an adequate immune response [
15]. In both CD and UC patients, high levels of IL-1β are found in the intestinal mucosa [
16] and stimulation by IL-1β leads to a more pronounced inflammatory response in CD immune cells compared to cells from healthy controls [
17]. The variant alleles of two
IL-1β promoter polymorphisms,
IL-1β T-31C and
IL-1β C-511T, have been found to be in almost complete linkage disequilibrium [
18], and the haplotypes encompassing the
IL-1β T-31C variant conferred higher transcription of
IL-1β compared to the wild type haplotype [
18]. The role of
IL-1β polymorphisms in IBD has been explored in several studies [
19‐
24]. These studies did not find any association with
IL-1β, however, the studies were rather small.
IL-10 is an anti-inflammatory cytokine, which leads to dampening of the activated immune system.
IL-10 knock-out mice develop colitis if they are not kept in germ-free environment [
25], and the administration of IL-10 ameliorates the inflammation in animal and
in vitro models [
26]. In patients, an impaired IL-10 production has been fund in severe cases of CD and UC [
27,
28]. Recently, a strong association between the marker rs3024505 immediately downstream of the IL-10 gene and adult UC was found in a genome-wide association study [
29]. This study also found a modest association between this marker and CD risk [
29]. However, no association was found for rs3024493, a linked polymorphism located in an intron in the
IL-10 gene, in a case-control study of paediatric onset CD [
30]. The
IL-10 promoter is polymorphic and genetic variation may account for different levels of cytokine production [
31]. The
IL-10 promotor polymorphisms G-1082A, C-819T, and C-592A have been most extensively studied. They are in tight linkage disequilibrium [
32] and the haplotype encompassing these three polymorphisms is associated with low IL-10 protein production in lymphocytes
in vitro [
32] and low of levels of circulating IL-10 protein in Kenyan children [
33] probably because the A allele of the
IL-10 promoter polymorphism C-592A leads to the formation of a binding site for the ETS family of transcription factors [
34]. Studies on the
IL-10 promoter polymorphisms and IBD susceptibility have been inconsistent [
22,
29‐
31,
35‐
40].
Heme oxygenase-1 (HO-1) is involved in the degradation of heme, thereby reducing oxidative stress and protecting against acute and chronic inflammation [
41]. Animal models of IBD have confirmed the anti-inflammatory effect of HO-1 [
42]. Hence, blockade of HO-1 activity results in exacerbation of experimental colitis whereas increased HO-1 pathway activity ameliorates experimental murine colitis [
43‐
45]. Carbon monoxide (CO) is one of the main metabolite of the HO-1 pathway and CO administration has been shown to ameliorate chronic colitis in IL-10 deficient mice [
42,
46]. In UC patients,
HO-1 expression and protein levels have been reported to be increased in inflamed colon compared to normal mucosa from patients with UC [
47]. Studies using luciferase reporter assays of a functional promoter polymorphism,
HO-1 A-413T, indicated that the A allele promoter had significantly higher activity than the T allele promoter [
48]. The AA genotype of this polymorphism has been associated with a reduced incidence of ischemic heart disease [
48]. Another promoter polymorphism, the
HO-1 (GT)N dinucleotide repeat polymorphism, was not associated with risk of inflammatory bowel disease [
49]. Interestingly, smoking affects the risk of IBD differentially, increasing the risk of CD and reducing the risk of UC [
50]. The mechanisms by which smoking affects risk of IBD is not clear and as tobacco smoke contains more than 3000 chemicals, several different mechanisms may be involved. Nicotine has been reported to modulate the immune balance in a Th1-dominant direction [
51] in accordance with the beneficial effect of smoking on UC. Moreover, smoking increases the production of certain pro-inflammatory cytokines, but, on the other hand, smoking is a source of carbon monoxide (CO). Thus, another possible mechanisms may involve interactions between smoking and IL-1β, IL-10 and HO-1 activity in relation to intestinal inflammation [
46].
In this study we wanted to assess the role of polymorphisms in IL-1β, IL-10, and HO-1 together with smoking in relation to risk of developing IBD in a Danish case-control study of 336 CD, 498 UC and 779 healthy controls, respectively.
Results
Characteristics of the Danish IBD patients and controls are shown in Table
1. A total of 834 Danish patients and 779 controls were included. 51% of the CD patients were current smokers at the time of diagnosis, whereas only 17% of the UC patients were current smokers. The genotype distributions among the controls did not deviate from Hardy-Weinberg equilibrium. The variant allele frequencies for
IL-1β T-31C,
IL-10 rs3024505, G-1082A, C-819T, C-592A and
HO-1 A-413T were 0.35, 0.18, 0.45, 0.21, 0.21, and 0.42, respectively, in the control group.
Table 1
The basic descriptions of the Danish study subjects1.
Gender: n (%) | | | |
male | 131 (39) | 241 (48) | 397 (51) |
female | 205 (61) | 257 (52) | 382 (49) |
Age: | | | |
Median (5%-95%) | 43 (23-77) | 49 (24-76) | 43 (23-60) |
Age at diagnosis: | | | |
Median (5%-95%) | 30 (15-65) | 35 (17-68) | |
Smoking habits: n(%) | | | |
Smokers | 170 (51) | 85 (17) | 204 (26) |
Never smokers | 120 (36) | 231 (46) | 391 (50) |
Former smokers | 46 (14) | 182 (37) | 184 (24) |
Location UC
2
: | | | |
Proctitis (E1) | | 211 (42) | |
Left side (E2) | | 183 (37) | |
Extensive (E3) | | 94 (19) | |
Data not available | | 10 (2) | |
Location CD
2
: n (%) | | | |
Colonic (L2) | 75 (22) | | |
Ileal (L1) | 155 (46) | | |
Ileocolonic (L3) | 93 (28) | | |
Data not available | 13 (4) | | |
Medication: n (%) | | | |
Advanced3
| 142 (42) | 104 (21) | |
No advanced medication4
| 189 (56) | 390 (78) | |
Data not available | 5 (1) | 4 (1) | |
Operation: n (%) | | | |
Yes | 153 (46) | 15 (3) | |
No | 176 (52) | 473 (95) | |
Data not available | 7 (2) | 10 (2) | |
Associations between polymorphisms and disease
Carriers of the variant allele of rs3024505 flanking the
IL-10 gene were at increased risk of both CD and UC. Homozygous variant allele carriers were at 2.48-fold (95% CI: 1.27-4.84) increased risk of CD and heterozygous carriers were at 1.31-fold (95% CI: 0.98-1.75) increased risk of CD after adjusting for age, gender and smoking status (Table
2). Homozygous variant allele carriers were at 2.31-fold (95% CI: 1.27-4.20) increased risk of UC and heterozygous carriers were at 1.34-fold (95% CI: 1.04-1.73) increased risk of UC after adjusting for age, gender and smoking status (Table
3). After correction for multiple testing the associations were borderline statistically significant. Minor allele frequencies of
IL-10 gene polymorphisms in selected studies are shown in Table
4.
Table 2
Genotypes in Danish patients with Crohns Disease1.
IL1 β C-31T (rs1143627) | | | | | | | | | |
TT | 165 | 342 | 1.00 | - | 1.00 | - | 1.00 | - | |
CT | 139 | 342 | 0.84 | (0.64-0.10) | 0.85 | (0.65-1.12) | 0.86 | (0.65-1.14) | 0.29 |
CC | 32 | 95 | 0.70 | (0.45-1.09) | 0.71 | (0.45-1.10) | 0.69 | (0.44-1.09) | 0.11 |
CT and CC | 171 | 437 | 0.81 | (0.63-1.05) | 0.82 | (0.63-1.07) | 0.82 | (0.63-1.07) | 0.15 |
IL-10 C-592A (rs1800872)
| | | | | | | | | |
CC | 214 | 483 | 1.00 | - | 1.00 | - | 1.00 | - | |
AC | 114 | 261 | 0.99 | (0.75-1.29) | 0.98 | (0.75-1.30) | 1.01 | (0.76-1.34) | 0.97 |
AA | 8 | 35 | 0.52 | (0.24-1.13) | 0.53 | (0.24-1.16) | 0.54 | (0.24-1.21) | 0.13 |
AC and AA | 122 | 296 | 0.93 | (0.71-1.21) | 0.93 | (0.71-1.22) | 0.95 | (0.72-1.25) | 0.72 |
IL-10 C-819T (rs1800871)
| | | | | | | | | |
CC | 216 | 483 | 1.00 | - | 1.00 | - | 1.00 | - | |
CT | 111 | 259 | 0.96 | (0.73-1.26) | 0.95 | (0.72-1.25) | 0.97 | (0.73-1.29) | 0.83 |
TT | 9 | 37 | 0.54 | (0.26-1.15) | 0.55 | (0.26-1.18) | 0.56 | (0.26-1.22) | 0.14 |
CT and TT | 120 | 296 | 0.91 | (0.69-1.18) | 0.90 | (0.69-1.18) | 0.92 | (0.70-1.21) | 0.55 |
IL-10 G-1082A (rs1800896)
| | | | | | | | | |
GG | 109 | 238 | 1.00 | - | 1.00 | - | 1.00 | - | |
AG | 171 | 374 | 1.00 | (0.75-1.33) | 0.99 | (0.74-1.33) | 0.97 | (0.72-1.32) | 0.87 |
AA | 56 | 167 | 0.73 | (0.50-1.07) | 0.75 | (0.51-1.10) | 0.78 | (0.53-1.16) | 0.23 |
AG and AA | 227 | 541 | 0.92 | (0.70-1.21) | 0.92 | (0.69-1.21) | 0.92 | (0.69-1.22) | 0.56 |
(rs3024505)
| | | | | | | | | |
CC | 203 | 522 | 1.00 | - | 1.00 | - | 1.00 | - | |
CT | 114 | 235 | 1.25 | (0.95-1.64) | 1.27 | (0.96-1.68) | 1.31 | (0.98-1.75) | 0.07 |
TT | 19 | 22 | 2.22 | (1.18-4.19) | 2.60 | (1.36-4.96) | 2.48 | (1.27-4.84) | 0.01 |
CT and TT | 133 | 779 | 1.33 | (1.02-1.73) | 1.37 | (1.05-1.80) | 1.40 | (1.06-1.85) | 0.02 |
HO-1 A-413T (rs2071746)
| | | | | | | | | |
AA | 110 | 267 | 1.00 | - | 1.00 | - | 1.00 | - | |
AT | 165 | 373 | 1.07 | (0.81-1.43) | 1.06 | (0.79-1.42) | 1.05 | (0.78-1.42) | 0.75 |
TT | 61 | 139 | 1.07 | (0.73-1.55) | 1.11 | (0.76-1.62) | 1.04 | (0.70-1.53) | 0.86 |
AT and TT | 226 | 512 | 1.07 | (0.82-1.41) | 1.08 | (0.82-1.42) | 1.05 | (0.79-1.39) | 0.75 |
Table 3
Genotypes in Danish patients with ulcerative colitis1.
IL1 β C-31T (rs1143627) | | | | | | | | | |
TT | 204 | 342 | 1.00 | - | 1.00 | - | 1.00 | - | |
CT | 238 | 342 | 1.17 | (0.92-1.48) | 1.15 | (0.90-1.47) | 1.15 | (0.89-1.47) | 0.28 |
CC | 56 | 95 | 0.99 | (0.68-1.43) | 0.99 | (0.68-1.46) | 1.02 | (0.69-1.49) | 0.94 |
CT and CC | 294 | 437 | 1.13 | (0.90-1.42) | 1.11 | (0.88-1.41) | 1.12 | (0.88-1.42) | 0.35 |
IL-10 C-592A (rs1800872)
| | | | | | | | | |
CC | 328 | 483 | 1.00 | - | 1.00 | - | 1.00 | - | |
AC | 149 | 261 | 0.84 | (0.66-1.07) | 0.83 | (0.65-1.07) | 0.83 | (0.64-1.07) | 0.14 |
AA | 21 | 35 | 0.88 | (0.51-1.55) | 0.99 | (0.56-1.76) | 1.00 | (0.56-1.77) | 0.99 |
AC and AA | 170 | 296 | 0.85 | (0.67-1.07) | 0.85 | (0.67-1.08) | 0.85 | (0.66-1.08) | 0.18 |
IL-10 C-819T (rs1800871)
| | | | | | | | | |
CC | 325 | 483 | 1.00 | - | 1.00 | - | 1.00 | - | |
CT | 151 | 259 | 0.87 | (0.68-1.11) | 0.86 | (0.67-1.11) | 0.85 | (0.66-1.10) | 0.22 |
TT | 22 | 37 | 0.88 | (0.51-1.53) | 1.00 | (0.57-1.74) | 1.00 | (0.57-1.75) | 0.99 |
CT and TT | 173 | 296 | 0.87 | (0.69-1.10) | 0.88 | (0.69-1.12) | 0.87 | (0.68-1.11) | 0.27 |
IL-10 G-1082A (rs1800896)
| | | | | | | | | |
GG | 169 | 238 | 1.00 | - | 1.00 | - | 1.00 | - | |
AG | 239 | 374 | 0.90 | (0.70-1.16) | 0.91 | (0.70-1.19) | 0.93 | (0.72-1.22) | 0.61 |
AA | 90 | 167 | 0.76 | (0.55-1.05) | 0.78 | (0.56-1.08) | 0.76 | (0.54-1.06) | 0.10 |
AG and AA | 329 | 541 | 0.86 | (0.67-1.09) | 0.87 | (0.68-1.12) | 0.88 | (0.68-1.13) | 0.31 |
(rs3024505)
| | | | | | | | | |
CC | 297 | 522 | 1.00 | - | 1.00 | - | 1.00 | - | |
CT | 172 | 235 | 1.29 | (1.01-1.64) | 1.35 | (1.05-1.73) | 1.34 | (1.04-1.73) | 0.02 |
TT | 29 | 22 | 2.32 | (1.31-4.11) | 2.37 | (1.31-4.29) | 2.31 | (1.27-4.20) | 0.01 |
CT and TT | 201 | 779 | 1.37 | (1.09-1.74) | 1.43 | (1.13-1.83) | 1.43 | (1.12-1.82) | 0.004 |
HO-1 A-413T (rs2071746)
| | | | | | | | | |
AA | 162 | 267 | 1.00 | - | 1.00 | - | 1.00 | - | |
AT | 251 | 373 | 1.11 | (0.86-1.43) | 1.10 | (0.85-1.42) | 1.11 | (0.85-1.44) | 0.45 |
TT | 85 | 139 | 1.01 | (0.72-1.41) | 1.00 | (0.71-1.41) | 1.01 | (0.71-1.42) | 0.98 |
AT and TT | 336 | 512 | 1.08 | (0.85-1.37) | 1.07 | (0.84-1.37) | 1.08 | (0.84-1.38) | 0.55 |
Table 4
Odds ratios and 95% confidence intervals (OR (CI)) for associations between IL-10 gene polymorphisms and ulcerative colitis (UC) or Crohns disease (CD) in selected case-control studies3.
UC | | | | | | | |
1855/3091 | 1.46 (1.31-1.62) | | Neg | Neg | neg | | |
203/391 | | | neg | | 1.66 (1.30-2.14) | | |
CD
| | | | | | | |
1848/1804 | 1.17 (1.01-1.34) | | | | | | |
270/336 | | neg | 0.77 (0.58-1.00) | | | 1.29 (1.01-1.64) | |
234-6/188-231 | | | | neg | neg | | |
No association was found between the
IL-1β,
IL-10 G-1082A, C-819T, C-592A,, and
HO-1 polymorphisms and risk of CD or UC (Table
2 and
3). The three
IL-10 promoter polymorphisms were found to be in almost complete linkage as previously described for Caucasians [
32]. Therefore, no haplotype analyses were performed.
No significant difference in the genotype distribution between CD and UC was found (data not shown). When combining UC and CD data to increase the statistical power there were still no associations between the IL-1β, the three IL-10 promoter polymorphisms, and HO-1 gene polymorphisms and risk of IBD (results not shown).
Subgroup analyses showed that variant allele carriers of rs3024505 were at 1.47-fold (95% CI: 1.10-1.96) and 1.35-fold (95% CI: 1.04-1.76) higher risk of a diagnosis of CD and UC, respectively, before the age of 40 years than the homozygous wildtype carriers (results not shown). No associations between rs3024505 genotype and disease localisation, or between IL-1β, the three IL-10 promoter polymorphisms, and HO-1 polymorphisms and age at diagnosis or disease localisation were found.
Gene-smoking interaction analyses
The effect of smoking habits at diagnosis on the genotype associations was investigated for CD and UC, respectively (Additional file
1: Interaction between the studied polymorphisms and smoking status in relation to risk of Crohns Disease and Additional file
2: Interaction between the studied polymorphisms and smoking status in relation to risk of ulcerative colitis). No consistent interactions between smoking status and any of the genotypes were found.
Discussion
The present case-control study showed that the rs3024505 marker polymorphism flanking the IL-10 gene was significantly associated with risk of CD and UC, and, furthermore, with risk of a diagnosis of CD and UC at young age. None of the polymorphisms IL-1β T-31C, IL-10 G-1082A, C-819T, C-592A, or HO-1 A-413T were associated with risk of CD, UC, or UC and CD combined. No consistent interactions between smoking status and genotypes were found.
Our results replicate the findings by Franke et al. [
29] (Table
4). In addition, we found that the association was carried by a stronger association in the younger age group. Franke et al found that the variant allele of rs3024505 was associated with increased risk of UC with OR of 1.46 (95% CI: 1.31-1.62) and with CD with OR of 1.17 (95% CI: 1.01-1.34). Furthermore, they found no association between the three
IL-10 promoter polymorphisms and risk of UC (results regarding CD were not reported). Previous studies were unable to find association between IBD and the
IL-10 promoter polymorphisms [
22,
31,
35,
39,
40] whereas other studies have found associations between paediatric onset of CD and
IL-10 C-819T wildtype allele [
30], Crs2222202T variant allele [
30] and between the
IL-10 G-1082A variant allele and risk of UC [
58] (Table
4).
The biological significance of rs3024505 in IBD remains unclear [
29]. The polymorphism is is located in an intergenic region proximal to the 3'UTR end of the
IL-10 gene. The region has a high potential for containing regulatory sequences, and may thus regulate
IL-10 gene expression [
29]. Furthermore, rs3024505 is in perfect linkage with other polymorphisms located within the
IL-10 gene [
29]. On the other hand, since no associations were found between risk of UC or CD and the
IL-10 promoter polymorphisms with proven functional effects on the
IL-10 gene expression, this may suggest either that the rs3024505 has a much stronger regulatory effect on IL-10 levels than the promoter polymorphisms or that the effect of the polymorphism on disease risk is unrelated to IL-10 expression.
IL-1β, IL-10 and HO-1 are key players in the homeostasis of the intestinal immune system. Due to their pro-inflammatory and anti-inflammatory effects they are of significance for the development and maintenance of chronic inflammation. IL-1β has pro-inflammatory effects, whereas IL-10 and HO-1 have anti-inflammatory effects. A substantial number of studies document the roles of the interleukins, including IL-1β and IL-10, and HO-1 in intestinal inflammation in various animal IBD models and in IBD patients [
15,
25,
26,
43‐
47]. Therefore, genetic variations in these genes may cause imbalance in intestinal homeostasis and thereby contribute to chronic inflammation. On this background,
IL-1β, IL-10 and
HO-1 are relevant candidates for IBD susceptibility genes.
Our results are in accordance with previous studies which were unable to find association between IBD and
IL-1β T-31C [
24], taqI [
19,
23] or C-511T [
20,
21]. The
HO-1 A-413T polymorphism has not previously been studied in relation to IBD, whereas no association was found between IBD and
HO-1 (GT)N [
49]. However, all these studies were small, the largest studies included 500 participants, and thus with limited statistical power to exclude an association. The polymorphisms analysed in the present study,
IL-1β T-31C, and
HO-1 A-413T have been shown to have biological effect [
18,
48,
59], and the SNPs have previously been associated to risk of various disease entities [
48,
60].
We found no consistent interactions between the studied polymorphisms and smoking in relation to risk of CD or UC. Although both smoking and nicotine administration lower the exaggerated IL-1β response in IBD patients [
61,
62], the present study does not indicate that smoking at the time of diagnosis influences IBD risk by pathways involving
IL-1β,
IL-10 or
HO-1, since the polymorphisms had no effect among present smokers. Cigarette smoke has been reported to act differentially on inflammation in the small and large intestine, thus worsening small intestinal inflammation, but ameliorating colitis [
63]. We were not able to perform subgroup analyses to target this question due to limited statistical power.
It is important to stress the strengths and limitations of the study. The present study included 1600 participants and power analyses showed that this study has more than 80% power to detect a dominant effect with an OR of 1.5 in relation to either CD or UC and or 1.4 if CD and UC were combined. Moreover, genetic determinants may be stronger among patients with extensive disease and ileal disease [
64,
65] and disease onset at low age. The effects of the polymorphisms might thus be below the detection level of our study.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
UV and AE carried out the genotyping. VA, HK, AE, MØ, BAJ established the cohort and/or participated in sample preparation and collection. JC and AT performed the statistical analyses. VA and UV conceived the genotyping study, and its design and coordination and wrote the manuscript. All authors read and approved the final manuscript.